Cardio Diagnostics Holdings, Inc. (CDIO)

NASDAQ: CDIO · IEX Real-Time Price · USD
1.110
+0.030 (2.78%)
At close: Apr 12, 2024, 4:00 PM
1.100
-0.010 (-0.90%)
After-hours: Apr 12, 2024, 7:13 PM EDT
2.78%
Market Cap 23.97M
Revenue (ttm) 17,065
Net Income (ttm) -8.38M
Shares Out 21.59M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 163,344
Open 1.100
Previous Close 1.080
Day's Range 1.060 - 1.130
52-Week Range 0.171 - 3.560
Beta 4.97
Analysts Buy
Price Target 8.00 (+620.72%)
Earnings Date May 13, 2024

About CDIO

Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 7
Stock Exchange NASDAQ
Ticker Symbol CDIO
Full Company Profile

Financial Performance

In 2023, CDIO's revenue was $17,065, an increase of 1696.32% compared to the previous year's $950. Losses were -$8.38 million, 79.7% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CDIO stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 620.72% from the latest price.

Price Target
$8.0
(620.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

CHICAGO--(BUSINESS WIRE)--Exponential Health adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests marking a new era in personalized and preventive cardiac care.

5 days ago - Business Wire

Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre

CHICAGO--(BUSINESS WIRE)--This collaboration aims to expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests.

10 days ago - Business Wire

Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology's 73rd Annual Scientific Session

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its HeartRisk and Actionable Clinical Intelligence platforms at the ACC's 73rd Annual Scientific Session.

4 weeks ago - Business Wire

Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced the issuance of its second U.S. patent.

5 weeks ago - Business Wire

Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.

2 months ago - Business Wire

Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' AI-driven epigenetic-genetic blood tests will be available Q2 2024 inside the Walmart Supercenter in Round Lake Beach, Illinois.

2 months ago - Business Wire

Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests

CHICAGO--(BUSINESS WIRE)--resTOR Longevity Clinic will offer Cardio Diagnostics' blood-based epigenetic-genetic cardiovascular disease tests.

2 months ago - Business Wire

Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor.

2 months ago - Business Wire

Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that India's Patent Office has granted a patent to the University of Iowa Research Foundation under patent number 484488.

3 months ago - Business Wire

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform.

3 months ago - Business Wire

Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform.

3 months ago - Business Wire

American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event

CHICAGO--(BUSINESS WIRE)--The AMA has granted and assigned Cardio Diagnostics a dedicated CPT® PLA for the company's AI-driven CHD event risk assessment test, Epi+Gen CHD.

3 months ago - Business Wire

American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.'s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that the AMA has assigned a dedicated CCPT® PLA) for the company's AI-driven CHD detection test, PrecisionCHD.

3 months ago - Business Wire

Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director.

4 months ago - Business Wire

Cardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. today announced it has regained Nasdaq minimum bid price requirement.

4 months ago - Business Wire

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference.

4 months ago - Business Wire

Cardio Diagnostics Holdings, Inc's Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference.

4 months ago - Business Wire

American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc's Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the AMA CPT Editorial Panel is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT PLA codes.

4 months ago - Business Wire

Cardio Diagnostics Holdings, Inc. Announces Breakthrough in Coronary Heart Disease Detection with PrecisionCHD Test, Published in the Journal of the American Heart Association

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA),.

5 months ago - Business Wire

Family Medicine Specialists Selects Cardio Diagnostics' Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients

CHICAGO--(BUSINESS WIRE)--Family Medicine Specialists has selected Cardio Diagnostics' tests to identify patients at risk for coronary heart disease events.

5 months ago - Business Wire

Cardio Diagnostics Holdings, Inc Receives Innovative Technology Contract from Vizient for Its Novel AI-Driven Precision Heart Disease Tests – Epi+Gen CHD & PrecisionCHD

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced its AI-driven molecular heart disease tests has received an Innovation Technology contract from Vizient, Inc.

5 months ago - Business Wire

Cardio Diagnostics Holdings, Inc and Aimil Ltd Join Forces to Introduce Cardiovascular Epigenetic Technologies to India

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced it has entered into a Supply and Distribution Agreement with Aimil Ltd.

6 months ago - Business Wire

Cardio Diagnostics Holdings, Inc Launches New Lab and Fulfillment Center, Paving Way for Expanded Testing Capacity, Reduced Costs, Reduced Turnaround Time and Improved Margins

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the launch of the Company's new integrated facility in Iowa City, Iowa.

6 months ago - Business Wire

Cardio Diagnostics Publishes Novel and Scalable Pathways to Enhance Global Coronary Heart Disease Care through Precision Epigenetics in Epigenomics

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics and Dr. Damon Broyles published an  article on scalable pathways that leverage precision epigenetics to revolutionize CHD.

7 months ago - Business Wire

Cardio Diagnostics Holdings, Inc. and Truckers Health Network Enter Into a Strategic Collaboration to Accelerate Cardiovascular Health Initiatives in the Trucking Industry

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced a collaboration with Truckers Health Network to Accelerate cardiovascular health initiatives in the trucking industry.

7 months ago - Business Wire